• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MICRO THERAPEUTICS, INC. DBA EV3 NV MICROCATHETER; CATHETER, CONTINUOUS FLUSH

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MICRO THERAPEUTICS, INC. DBA EV3 NV MICROCATHETER; CATHETER, CONTINUOUS FLUSH Back to Search Results
Model Number UNK-NV-MICROCATH
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Paralysis (1997)
Event Date 09/26/2019
Event Type  Injury  
Manufacturer Narrative
Reported patient age is representative of the average patient age in the study, not necessarily of the patient who experienced the reported adverse event.The reported patient sex is representative of the majority of patient included in the study, not necessarily of the patient who experienced the reported adverse event.If information is provided in the future, a supplemental report will be issued.
 
Event Description
Xu, b., wang, z., bai, w., & li, t.(2019).Treatment of cavernous sinus dural arteriovenous fistula using different surgical approaches: analysis of 32 consecutive cases. journal of interventional medicine, 2(3), 118¿122.Https://doi.Org/10.1016/j.Jimed.2019.09.011 medtronic review of the literature article found described the review of 32 cases from a single facility in which cavernous sinus dural arteriovenous fistula (csdavf) was treated between may 2009 and may 2014.There were 25 female patient and 7 male patients in the study population.The average age was 50.8 years.The manifestations on digital subtraction angiography (dsa) were classified according to barrow types, with 15 cases of type c simple external carotid artery dural shunts, and 17 cases of dural shunts from the meningeal branches of the external and internal carotid arteries.All patients had ophthalmic venous drainage, though type/location varied.All patients underwent routine diagnostic dsa prior to surgery.Type of embolization procedure and approach was determined based on angioarchitectural features, these being: 1) blood supply, 2) position of the davf (front, simple blood-supplying artery; back, vein approach), and 3) draining vein.8 patients included in the study underwent treatment through iaa (inferior arterial approach).In these procedures the right femoral artery was punctured, a 5/6f artery sheath was implanted, and the proper blood-supplying artery was chosen based on the diameter, length, tortuosity, and type of collateral branch determined using super-selective angiography.An echelon-10 or marathon microcatheter was used to super-selectively approach the cavernous sinus fistula with the aid of a micro guidewire, and the angioarchitecture was revealed through super-selective angiography, thus avoiding dangerous anastomoses.Spring coil embolization was performed on the fistula to slow down the blood flow, when necessary.Subsequently, onyx les was slowly injected using the roadmap-bolus-diffusion-pause-roadmap-bolus method.Angiography was repetitively conducted during the onyx injection to observe the status of the cavernous sinus embolization.The surgery was terminated once the fistula disappeared.Among eight iaa cases, two cases were failures and were successfully embolized through ipsa.Six cases were treated with onyx embolization alone (including one case that failed with the venous approach and was switched to iaa), and one was treated with spring coils combined with onyx embolization.One patient treated with the iaa approach method, experienced prosopoplegia considered to be related to procedure related which impr oved.No additional medical or surgical treatment was reported.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
NV MICROCATHETER
Type of Device
CATHETER, CONTINUOUS FLUSH
Manufacturer (Section D)
MICRO THERAPEUTICS, INC. DBA EV3
9775 toledo way
irvine CA 92618
Manufacturer (Section G)
MICRO THERAPEUTICS, INC. DBA EV3
9775 toledo way
irvine CA 92618
Manufacturer Contact
david gustafson
9775 toledo way
irvine, CA 92618
7635149628
MDR Report Key11665881
MDR Text Key247662255
Report Number2029214-2021-00425
Device Sequence Number1
Product Code KRA
Combination Product (y/n)N
Reporter Country CodeCH
PMA/PMN Number
K093750
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,literature
Reporter Occupation Physician
Type of Report Initial
Report Date 04/14/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received04/14/2021
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberUNK-NV-MICROCATH
Device Catalogue NumberUNK-NV-MICROCATH
Device Lot NumberUNKNOWN
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received03/26/2021
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Disability;
Patient Age50 YR
-
-